{"id":"NCT00490971","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","briefTitle":"A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder","officialTitle":"A Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an Acute Manic or Mixed Episode Associated With Bipolar I Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05","primaryCompletion":"2010-04","completion":"2010-04","firstPosted":"2007-06-25","resultsPosted":"2012-03-05","lastUpdate":"2015-04-15"},"enrollment":768,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"Olanzapine","otherNames":[]},{"type":"DRUG","name":"Paliperidone ER","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Paliperidone ER","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Olanzapine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the effectiveness and safety of oral extended-release (ER) paliperidone compared with placebo in the prevention of the recurrence of mood symptoms in patients with Bipolar I Disorder who initially respond to treatment of an acute manic or mixed episode with paliperidone ER. Olanzapine was included as an active control arm, although the study is not designed to allow for a direct comparison of olanzapine with paliperidone.","primaryOutcome":{"measure":"Time to Recurrence of Any Mood Symptoms (Manic or Depressive) Associated With Bipolar I Disorder","timeFrame":"Date of randomization into the maintenance phase until the first occurrence of recurrence of any symptoms or discontinuation from the study, assessed over a period of 41 months.","effectByArm":[{"arm":"Pali/Placebo","deltaMin":85,"sd":null},{"arm":"Pali/Pali","deltaMin":140,"sd":null},{"arm":"Olan/Olan","deltaMin":541,"sd":null}],"pValues":[{"comp":"OG002","p":"0.017"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":78,"countries":["United States","Bulgaria","China","Costa Rica","France","Germany","India","Malaysia","Panama","Poland","Romania","Russia","Serbia","South Africa","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["22377512"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":42,"n":614},"commonTop":["Insomnia","Headache","Somnolence","Weight increased","Akathisia"]}}